GSK-3β activation has been associated with prostate cancer progression [9], and inactivation of this enzyme activates a p53-dependent apoptosis pathway resulting in a diminished colorectal cancer cell growth [10]. This evidence concerns the gene GSK3B and colorectal cancer.